Piper Jaffray Upgrades Pacific Biosciences of California (PACB) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pacific Biosciences of California, Inc. (PACB) Tops Q2 EPS by 2c
August 1, 2013 5:23 PM EDTPacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35).
For earnings history and earnings-related data on Pacific Biosciences of California, Inc. (PACB) click here.... More
